Advanced in Conjunctivitis with Pseudomembrane

Junichi Tomomatsu

Tokyo, JP 
Advanced in Conjunctivitis with Pseudomembrane
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Junichi Tomomatsu practices in Tokyo, Japan. Mr. Tomomatsu is rated as an Advanced expert by MediFind in the treatment of Conjunctivitis with Pseudomembrane. His top areas of expertise are Adult Soft Tissue Sarcoma, Conjunctivitis with Pseudomembrane, Lung Metastases, Liposarcoma, and Laryngectomy.

His clinical research consists of co-authoring 49 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Conjunctivitis with Pseudomembrane.

Gender
Male

Locations

Tokyo, 1358550, Japan
Other Locations
Ariake, 1358550, Japan
Japan
Koto, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Enrollment Status: Terminated
Publish Date: June 13, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 3

49 Total Publications

Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinib.
Sporadic medullary thyroid carcinoma with a rare RET transmembrane domain mutation (A641R) that responds to selpercatinib.
Journal: The oncologist
Published: May 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tomomatsu's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile